Washington University School of Medicine
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.
Inclusion Criteria: * Men and women, 21-99 years of age and any race * Normal left ventricular function (left ventricular ejection fraction (LVEF) \>50%) as determined by echocardiography * HER2 positive or negative breast cancer patients or lymphoma patients * Designated to receive standard of care (SOC) treatment with an anthracycline-containing regimen including combination therapy * Patients willing to adhere to fasting for 15 hours before 18F-FDG PET imaging studies (if applicable) Exclusion Criteria: * Inability to receive and sign informed consent * Prior exposure to anthracyclines o…
68Ga-Galmydar is a positron-emitting radioisotope used prior to PET/MRI imaging. Prior to imaging, patients will receive one single intravenous administration of 2.5 mCi ± 20% (2.0-3.0 mCi) of 68Ga-Galmydar followed by a 10 mL normal saline flush on Imaging Day -1.
Patients will undergo PET/MRI according to standard of care imaging.
18F-FDG is administered by an intravenous injection of 10 mCi ± 20% (8-12 mCi) followed by a 10 mL normal saline flush.
Arctuva estimate
Verify or correct the compensation shown for this listing.